erythromycin-resistant isolates.
Interest in macrolide antibiotics has been rekindled by the new uses of the erythromycin for treatment of infections due to organisms such as Legionella spp. and Campylobacter spp. Erythromycin has a long history of successful use as an alternative to penicillin against many grampositive bacteria. However, it does produce significant gastrointestinal discomfort in many adults. Midecamycin (Fig. 1) is a macrolide in which an acetoxy group is substituted on position 9 of the 16-member ring and on position 4 of the terminal sugar. It has been reported to act against some erythromycin-and josamycin-resistant bacteria (1). Midecamycin is alleged to have no bitter taste, and it can be administered orally with good absorption (1).
Midecamycin was a gift from the Central 
